MMV-1581361 combines strong antimalarial efficacy with transmission blockade

AI Briefing

• – MMV-1581361 is a Pf ATP4 inhibitor identified by researchers at GSK plc and its collaborators.
• – The compound showed strong antimalarial efficacy in models of malaria.
• – MMV-1581361 was developed through structure-activity relationship studies of its precursor MMV-020136.